Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by deeppocket83on Jan 25, 2017 8:39am
116 Views
Post# 25751454

JPY / Salix / Takeda

JPY / Salix / TakedaSo when the originally offer came through from Takeda the YPN was trading at 103 to 1US. When the negotiations took a break in December it was trading at 117 to 1US. Thats why Takeda wanted a billion discount because they lost a 1 billion on the currency exchange. They are budgeting 15 billion for aquisitions. So with the aquisition they made beginning of the year they would of had enough money for both aquisitions. Expect  round 2 to occur when the JPY strengthens, should be in another month or so as Japan's economy is recovering fairly quickly. And this month JPY is starting to recover. https://www.xe.com/currencycharts/?from=USD&to=JPY&view=1Y

<< Previous
Bullboard Posts
Next >>